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To the Editor, 
We thank Dr Zembrzuska for her letter relating to our systematic review and network meta-
analysis describing the impact of targeted pharmacological treatments on mental health 
outcomes in rheumatoid arthritis (RA) [1]. She highlights clearly the disparity in approach 
towards managing physical versus mental comorbidities in rheumatological practice. 
Approximately one in four people with RA will also have symptoms of depression [2] and there 
has been extensive recent research conducted by us here at King’s College London, and by 
colleagues worldwide emphasising the impact common mental disorders such as symptoms 
of depression and anxiety may have on long-term physical health outcomes and treatment 
response in RA [3-6]. The consequences of mental comorbidity in the context of RA are clear: 
patients have significantly impaired long-term functioning and may not respond well to 
expensive treatments.  
There are some small-scale local examples of excellent progress made in this area. The 
Integrating Mental and Physical Healthcare: Research, Training and Services (IMPARTS) 
project provides a generic platform for web-based patient reported outcome measurement 
including mental health screening which allows all patients attending general hospital 
outpatient appointments to be assessed for symptoms of depression and anxiety as part of 
routine clinical practice [7]. This system links with electronic health records, allowing routinely 
collected physical and psychological symptoms to be immediately available for review by the 
treating clinician, with advice for onward referrals and links with hospital and community-based 
mental health services where available. In the UK, the NHS-funded programme Improving 
Access to Psychological Therapies (IAPT) began offering new services for people with long 
term conditions in 2018, which may go some way to address this unmet need. Whilst there 
are also some examples of dedicated psychology time allocated to rheumatology clinics, there 
is a huge need for standardisation in the funding of such roles to ensure all patients have equal 
access to psychosocial support.  
Depression and anxiety in the context of physical disease are treatable [8-9] and data from 
other disease areas suggests that successfully managing psychiatric co-morbidities is likely 
to be cost-effective [10-11]. The implementation of effective mental health care into routine 
practice is dependent on commissioning policies funding sustainable systems of integrated 
health management, changes in organisational structure and professional flexibility, and the 
design of pragmatic interventions relevant to the context of delivery. Providing dedicated 
mental health care within the context of clinical disease management, as suggested by Dr 
Zembrzuska, is essential to achieve parity of esteem and improve patients’ physical health, 
response to treatment, and overall quality-of-life. 
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